The study pesented at the American Diabetes Association 77th Scientific Sessions compared Mylan/Biocon’s MYL-1501D, a proposed biosimilar to Sanofi-Aventis’ insulin glargine, with the reference product.
A double-blind, randomized, 3-way crossover study comparing the pharmacokinetics (PK) and pharmacodynamics (PD) of MYL-1501D, Mylan/Biocon’s proposed biosimilar to Sanofi-Aventis’ originator insulin glargine (US and EU versions of Lantus) reported PK/PD equivalence between the 3 products in 114 patients with type 1 diabetes (T1D). The findings, presented during a poster session at the American Diabetes Association 77th Scientific Sessions on June 10, 2017, in San Diego, also showed that both insulin glargine and the biosimilar were generally well tolerated and did not display significant safety issues.
Lead researcher Tim Heise, MD, of Profil Institut fur Stoffwechselforschung GmbH, Neuss, Germany, and colleagues noted that the study’s analysis of PK/PD factors were performed to meet the guidance issued by the FDA and the European Medicines Agency (EMA) on the development and approval of biosimilars to show biosimilars are comparable to the originator biologic product. Therefore, the objective of the study was to evaluate PK/PD bioequivalence with regard to total and maximum plasma insulin concentrations of the 3 insulin glargine preparations, each administered by subcutaneous injection of a single dose of 0.4 U/kg in patients with T1D.
Patients included in the study were generally healthy male or female nonsmokers aged 18 to 55 years who had a body mass index between 18.5 and 29.9 kg/m2 and were on stable insulin treatment for at least 6 months before the screening visit. Patients with insulin resistance were excluded from the study.
The study met its primary PK endpoints; mean serum insulin and plasma metabolite concentration profiles of the 3 insulin glargine preparations were shown to be similar. Additionally, the 3 drugs had nearly identical glucose infusion rate (GIR) profiles, which was the primary PD endpoint. Thus, the study demonstrated bioequivalence of MYL-1501D and the US and EU versions of Lantus in T1D patients for the primary PK and PD end points.
Rates of adverse events (AEs) observed were similar for the 3 insulin glargine formulations, with no serious AEs or AEs leading to withdrawal.
Currently, the only FDA-approved “follow-on” insulin product in the United States is Eli Lilly’s Basaglar, a biosimilar of Sanofi’s Lantus, which was approved in late 2015. The FDA is currently reviewing other insulin glargine analogs.
Mylan announced that the data presented from this study and others on MYL1501D in patients with type 1 and type 2 diabetes confirmed its efficacy, safety, and immunogenicity in comparison with Lantus.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Commercial Biosimilar Coverage Is on the Rise, but Preferences Still Vary
October 28th 2023A poster from AMCP Nexus quantifies trends in biosimilar coverage within Tufts Medical Center, finding that payer coverage of these products has increased but individual preferences among payers still vary.
"Not So Different": How the BPCIA Transition Will Affect Biosimilar Uptake
April 10th 2020This week on the podcast, we’re speaking with the executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), Cate Lockhart, PharmD, PhD, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how the new approval pathway for biologics will affect the pace at which biosimilars come to market.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.
Biosimilars Check-In: BI Launches Unbranded Adalimumab; New Omalizumab Deal; CRL for Insulin Aspart
October 10th 2023Boehringer Ingelheim (BI) launches an unbranded version of its adalimumab biosimilar; Alvotech and Kashiv Biosciences partner for an omalizumab biosimilar candidate; the FDA issues a complete response letter (CRL) for Biocon’s insulin aspart biosimilar.